Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings describe new data in breast cancer research
February 24th, 2005
Breast cancer research advances have been reported from the United Kingdom, United States and Denmark. Study 1: According to a study from England, "Following tamoxifen, the first selective estrogen receptor modulator (SERM), a number of other antiestrogens have been developed." "The first-generation SERMs exhibit cross-resistance with tamoxifen and have agonist effects on the uterus. Toremifene has equal efficacy to tamoxifen and may be useful as a tamoxifen alternative. Efficacy results for droloxifene and idoxifene were disappointing and their clinical development ceased," said J.F.R. Robertson and colleagues, City Hospital, Nottingham. ...
Source: Women's Health Weekly (2005-02-24)
|
